SG11201809089QA - Bispecific binding proteins and uses thereof - Google Patents
Bispecific binding proteins and uses thereofInfo
- Publication number
- SG11201809089QA SG11201809089QA SG11201809089QA SG11201809089QA SG11201809089QA SG 11201809089Q A SG11201809089Q A SG 11201809089QA SG 11201809089Q A SG11201809089Q A SG 11201809089QA SG 11201809089Q A SG11201809089Q A SG 11201809089QA SG 11201809089Q A SG11201809089Q A SG 11201809089QA
- Authority
- SG
- Singapore
- Prior art keywords
- medlmmune
- gaithersburg
- llc
- way
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332788P | 2016-05-06 | 2016-05-06 | |
| PCT/US2017/031356 WO2017193032A2 (en) | 2016-05-06 | 2017-05-05 | Bispecific binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809089QA true SG11201809089QA (en) | 2018-11-29 |
Family
ID=60203374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809089QA SG11201809089QA (en) | 2016-05-06 | 2017-05-05 | Bispecific binding proteins and uses thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10457732B2 (enExample) |
| EP (1) | EP3452089B1 (enExample) |
| JP (5) | JP6952716B2 (enExample) |
| KR (3) | KR102490183B1 (enExample) |
| CN (1) | CN109152835B (enExample) |
| AR (1) | AR108377A1 (enExample) |
| AU (3) | AU2017260365B2 (enExample) |
| BR (1) | BR112018072485A2 (enExample) |
| CL (1) | CL2018003136A1 (enExample) |
| CO (1) | CO2018012415A2 (enExample) |
| IL (3) | IL321475A (enExample) |
| MA (1) | MA44885A (enExample) |
| MX (2) | MX2018013548A (enExample) |
| MY (1) | MY200335A (enExample) |
| RU (2) | RU2022102446A (enExample) |
| SG (1) | SG11201809089QA (enExample) |
| TW (3) | TWI890267B (enExample) |
| WO (1) | WO2017193032A2 (enExample) |
| ZA (1) | ZA201808160B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3277321T3 (da) | 2015-04-01 | 2024-09-02 | Anaptysbio Inc | Antistoffer, der er rettet mod T-celle-immunglobulin og mucin-protein 3 (TIM-3) |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| WO2017100372A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| WO2017218707A2 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| EP4342912A3 (en) * | 2016-09-23 | 2024-05-22 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| MA46113A (fr) * | 2016-11-01 | 2019-07-10 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3) |
| TWI841209B (zh) | 2017-01-09 | 2024-05-01 | 美商提薩羅有限公司 | 用抗tim-3抗體治療癌症之方法 |
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| WO2018193063A2 (en) | 2017-04-19 | 2018-10-25 | Institute For Research In Biomedicine | Novel malaria vaccines and antibodies binding to plasmodium sporozoites |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| JP7383617B2 (ja) * | 2017-12-28 | 2023-11-20 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Ｐｄ－ｌ１に対する抗体及びそのバリアント |
| TWI864129B (zh) | 2017-12-29 | 2024-12-01 | 圓祥生技股份有限公司 | 調節免疫檢查點作為癌症治療的單特異性蛋白質、其醫藥組成物、其核酸、及其用途 |
| WO2019233413A1 (en) | 2018-06-05 | 2019-12-12 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Dimer and use thereof |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| IL280002B2 (en) | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| CN119735694A (zh) | 2018-11-13 | 2025-04-01 | 指南针制药有限责任公司 | 对抗检查点分子的多特异性结合构建体及其用途 |
| WO2020198683A1 (en) * | 2019-03-28 | 2020-10-01 | Ab Studio Inc. | Heteromultimeric proteins and methods of use thereof |
| JP2022525238A (ja) * | 2019-04-01 | 2022-05-11 | インメタス セラピューティクス， インコーポレイテッド | 腫瘍微小環境および免疫チェックポイントタンパク質を標的とする二重特異性結合分子 |
| CN110229232B (zh) * | 2019-06-19 | 2020-05-19 | 北京智仁美博生物科技有限公司 | 双特异性抗体及其用途 |
| EP4047021A4 (en) * | 2019-10-17 | 2023-11-22 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | BISPECIFIC OX40/PD1-L1 ANTIBODIES |
| CN114786720B (zh) * | 2019-12-05 | 2025-08-22 | 艾贝乐医药科技有限公司 | TriAx抗体的组合物及其制备和使用方法 |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| JP7014250B2 (ja) | 2020-03-27 | 2022-02-01 | フジテック株式会社 | エレベータのドア装置用の動作設定装置、及び該動作設定装置を用いたドア装置の開閉動作の設定方法。 |
| BR112023001487A2 (pt) * | 2020-07-27 | 2023-02-14 | Macrogenics Inc | Método para tratar um câncer, método para estimular células imunes, kit farmacêutico e uso do kit farmacêutico |
| EP4225373A4 (en) | 2020-10-07 | 2025-01-08 | Dren Bio, Inc. | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF |
| CN114573704B (zh) * | 2021-03-10 | 2022-11-01 | 北京拓界生物医药科技有限公司 | Pd-1/ctla-4结合蛋白及其医药用途 |
| EP4323003A4 (en) * | 2021-04-13 | 2025-04-30 | MedImmune, LLC | Bispecific antibody targeting pd-1 and tim-3 |
| MX2023012324A (es) * | 2021-04-20 | 2023-10-30 | Amgen Inc | Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. |
| JP2024516616A (ja) | 2021-04-23 | 2024-04-16 | スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． | Ｔｉｍ－３を標的とする抗体及びその使用 |
| CR20230476A (es) * | 2021-04-30 | 2024-01-30 | Medimmune Llc | Proteínas de unión a pd-1 y tigit biespecíficas y usos de estas |
| KR20240153603A (ko) * | 2022-03-07 | 2024-10-23 | 메디뮨 엘엘씨 | Ctla-4 및 pd-1 이중특이적 항체를 사용한 치료 방법 |
| CA3263276A1 (en) * | 2022-07-28 | 2024-02-01 | Medimmune, Llc | Polytherapy for the treatment of cancer |
| KR20250040960A (ko) | 2022-07-28 | 2025-03-25 | 아스트라제네카 유케이 리미티드 | 항체-약물 접합체 및 이중특이적 체크포인트 억제제의 조합 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| US20240392005A1 (en) * | 2023-04-13 | 2024-11-28 | Medimmune, Llc | Pd-1/tigit binding proteins for cancer treatment |
| WO2024236529A1 (en) | 2023-05-17 | 2024-11-21 | Astrazeneca Ab | Methods and combinations for treating cervical cancer |
| TW202511292A (zh) * | 2023-05-23 | 2025-03-16 | 美商麥迪紐有限責任公司 | 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白 |
| TW202523359A (zh) | 2023-10-24 | 2025-06-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2649037T3 (es) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| US20050226867A1 (en) | 2003-10-08 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | IL-5R-specific antibody composition |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1896071T3 (en) | 2005-06-30 | 2015-05-26 | Janssen Biotech Inc | Methods and compositions with increased therapeutic activity |
| EP2455100A3 (en) | 2005-11-07 | 2012-11-07 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| ES2613963T3 (es) | 2008-01-18 | 2017-05-29 | Medimmune, Llc | Anticuerpos manipulados con cisteína para conjugación específica de sitio |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| PT2519543T (pt) * | 2009-12-29 | 2016-10-07 | Emergent Product Dev Seattle | Proteínas de ligação de heterodímero e suas utilizações |
| JP2013523179A (ja) | 2010-04-13 | 2013-06-17 | メディミューン，エルエルシー | フィブロネクチンタイプｉｉｉドメインに基づく多量体足場 |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| PT2794905T (pt) * | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
| NZ701821A (en) * | 2012-04-30 | 2016-06-24 | Biocon Ltd | Targeted/immunomodulatory fusion proteins and methods for making same |
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EP2832671B1 (en) | 2013-07-30 | 2016-07-13 | Hewlett-Packard Industrial Printing Ltd. | Printing apparatus and methods |
| BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| CN103721255A (zh) * | 2014-01-07 | 2014-04-16 | 苏州大学 | 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途 |
| WO2015112534A2 (en) * | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| BR112016027881A2 (pt) | 2014-05-29 | 2017-10-24 | Medimmune Ltd | antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv |
| CN106456608B (zh) * | 2014-06-06 | 2020-08-28 | 雷德伍德生物科技股份有限公司 | 抗her2抗体-美登木素缀合物及其使用方法 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CA2964367C (en) * | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| AU2016370376B2 (en) * | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
-
2017
- 2017-05-04 AR ARP170101161A patent/AR108377A1/es unknown
- 2017-05-04 IL IL321475A patent/IL321475A/en unknown
- 2017-05-05 KR KR1020187034042A patent/KR102490183B1/ko active Active
- 2017-05-05 TW TW113101203A patent/TWI890267B/zh active
- 2017-05-05 RU RU2022102446A patent/RU2022102446A/ru unknown
- 2017-05-05 AU AU2017260365A patent/AU2017260365B2/en active Active
- 2017-05-05 SG SG11201809089QA patent/SG11201809089QA/en unknown
- 2017-05-05 CN CN201780027207.XA patent/CN109152835B/zh active Active
- 2017-05-05 US US15/588,271 patent/US10457732B2/en not_active Ceased
- 2017-05-05 EP EP17793480.9A patent/EP3452089B1/en active Active
- 2017-05-05 RU RU2018142544A patent/RU2766199C2/ru active
- 2017-05-05 MY MYPI2018704132A patent/MY200335A/en unknown
- 2017-05-05 WO PCT/US2017/031356 patent/WO2017193032A2/en not_active Ceased
- 2017-05-05 MX MX2018013548A patent/MX2018013548A/es unknown
- 2017-05-05 TW TW106115065A patent/TWI757290B/zh active
- 2017-05-05 JP JP2018557864A patent/JP6952716B2/ja active Active
- 2017-05-05 BR BR112018072485-8A patent/BR112018072485A2/pt active Search and Examination
- 2017-05-05 KR KR1020237001553A patent/KR102674279B1/ko active Active
- 2017-05-05 IL IL262437A patent/IL262437B2/en unknown
- 2017-05-05 MA MA044885A patent/MA44885A/fr unknown
- 2017-05-05 KR KR1020247018987A patent/KR20240096787A/ko active Pending
- 2017-05-05 TW TW111104211A patent/TWI831124B/zh active
-
2018
- 2018-11-05 CL CL2018003136A patent/CL2018003136A1/es unknown
- 2018-11-06 MX MX2022015901A patent/MX2022015901A/es unknown
- 2018-11-19 CO CONC2018/0012415A patent/CO2018012415A2/es unknown
- 2018-12-03 ZA ZA2018/08160A patent/ZA201808160B/en unknown
-
2019
- 2019-09-13 US US16/570,966 patent/US11279759B2/en active Active
-
2020
- 2020-07-06 AU AU2020204497A patent/AU2020204497B2/en active Active
-
2021
- 2021-06-30 US US17/364,539 patent/USRE49908E1/en active Active
- 2021-09-28 JP JP2021158292A patent/JP7171867B2/ja active Active
- 2021-12-14 US US17/550,219 patent/US20220251204A1/en not_active Abandoned
-
2022
- 2022-11-04 JP JP2022177063A patent/JP2023012528A/ja active Pending
- 2022-11-16 IL IL298286A patent/IL298286B2/en unknown
-
2023
- 2023-07-27 AU AU2023208166A patent/AU2023208166A1/en active Pending
-
2024
- 2024-01-17 JP JP2024005009A patent/JP7651022B2/ja active Active
- 2024-09-11 US US18/882,194 patent/US20250074986A1/en active Pending
-
2025
- 2025-03-12 JP JP2025039002A patent/JP2025090743A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201910206QA (en) | Methods and compositions for treating inflammatory gastrointestinal disorders | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function |